WEST PHARMACEUTICAL SERVICES, INC. |
Pennsylvania | 1-8036 | 23-1210010 | ||
(State or other jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
530 Herman O. West Drive, Exton, PA | 19341-0645 | |||
(Address of principal executive offices) | (Zip Code) |
Not Applicable |
(Former name or address, if changed since last report) |
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
• | A senior unsecured, multi-currency revolving credit facility of $300,000,000, with sublimits of up to $30,000,000 for swing line loans and up to $30,000,000 for the issuance of standby letters of credit, which credit facility may be increased from time to time by up to $100,000,000 in the aggregate through an increase in the revolving credit facility subject to the satisfaction of certain conditions; |
• | A termination date of October 14, 2020; |
• | Borrowings under the credit facility bear interest at either the base rate (the per annum interest rate of the highest of the Prime Rate, the Federal Funds Open Rate plus 50 basis points or the daily London Interbank Offered Rate ("LIBOR")) or at the applicable LIBOR rate, plus a tiered margin based on the ratio of the Company's total debt to its modified EBITDA, on a consolidated basis, ranging from 0 to 75 basis points for base rate loans and 100 to 175 basis points for LIBOR rate loans; |
• | Financial covenants providing that the Company shall not permit: the ratio of the Company's total debt to its modified EBITDA, on a consolidated basis, to be greater than 3.5 to 1; the ratio of the Company's EBIT to its interest expense, on a consolidated basis, to be less than 2.5 to 1; and the amount of outstanding priority debt to exceed 25% of the Company's consolidated capitalization; |
• | Customary limitations on liens securing indebtedness of the Company and its subsidiaries, fundamental changes (mergers, consolidations, liquidations and dissolutions), asset sales, distributions and acquisitions; and |
• | Customary events of default, the occurrence of which may result in the acceleration of any outstanding loans. |
(d) | Exhibits | |
10.1 | Credit Agreement, dated as of October 15, 2015, between West, certain of its subsidiaries, the lenders party thereto from time to time, PNC Bank, National Association, as Administrative Agent, Bank of America, N.A., Wells Fargo Bank, National Association and U.S. Bank National Association, as Syndication Agents, Citizens Bank of Pennsylvania and TD Bank, N.A., as Documentation Agents, and JPMorgan Chase Bank, N.A., HSBC Bank USA, National Association, and Northern Trust Company. PNC Capital Markets, LLC, was Sole Lead Arranger and Sole Bookrunner. |
WEST PHARMACEUTICAL SERVICES, INC. | |
/s/ William J. Federici | |
William J. Federici | |
Senior Vice President and Chief Financial Officer | |
October 19, 2015 |
Exhibit No. | Description |
10.1 | Credit Agreement, dated as of October 15, 2015, between West, certain of its subsidiaries, the lenders party thereto from time to time, PNC Bank, National Association, as Administrative Agent, Bank of America, N.A., Wells Fargo Bank, National Association and U.S. Bank National Association, as Syndication Agents, Citizens Bank of Pennsylvania and TD Bank, N.A., as Documentation Agents, and JPMorgan Chase Bank, N.A., HSBC Bank USA, National Association, and Northern Trust Company. PNC Capital Markets, LLC, was Sole Lead Arranger and Sole Bookrunner. |